The FDA introduced a generative AI tool called Elsa to improve its scientific research operations. Elsa, hosted in a secure environment, aims to speed up clinical reviews and scientific evaluations. Designed as a large language model, it assists FDA employees by summarizing internal documents and generating code for database development. FDA leadership views Elsa as the first step towards a broader integration of AI in their processes, with plans to expand its capabilities as it evolves. The rollout, initially scheduled for June 30, occurred ahead of time, following a successful pilot phase.
Today marks the dawn of the AI era at the FDA with the release of Elsa, AI is no longer a distant promise but a dynamic force enhancing and optimizing the performance and potential of every employee.
The introduction of Elsa is the initial step in the FDA's overall AI journey. As the tool matures, the agency has plans to integrate more AI in different processes.
Collection
[
|
...
]